: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy considered curable by modern clinical management. Nevertheless, the prognosis for T-ALL high-risk cases or patients with relapsed and refractory disease is still dismal. Therefore, there is a keen interest in developing more efficient and less toxic therapeutic approaches. T-ALL pathogenesis is associated with Notch signaling alterations, making this pathway a highly promising target in the fight against T-ALL. Here, by exploring the anti-leukemic capacity of the natural polyphenol curcumin and its derivatives, we found that curcumin exposure impacts T-ALL cell line viability and decreases Notch signaling in a dose- and time-dependent fashion. However, our findings indicated that curcumin-mediated cell outcomes did not depend exclusively on Notch signaling inhibition, but might be mainly related to compound-induced DNA-damage-associated cell death. Furthermore, we identified a novel curcumin-based compound named CD2066, endowed with potentiated anti-proliferative activity in T-ALL compared to the parent molecule curcumin. At nanomolar concentrations, CD2066 antagonized Notch signaling, favored DNA damage, and acted synergistically with the CDK1 inhibitor Ro3306 in T-ALL cells, thus representing a promising novel candidate for developing therapeutic agents against Notch-dependent T-ALL.
Identification of a novel curcumin derivative influencing notch pathway and DNA damage as a potential therapeutic agent in T-ALL / Zhdanovskaya, Nadezda; Lazzari, Sara; Caprioglio, Diego; Firrincieli, Mariarosaria; Maioli, Chiara; Pace, Eleonora; Imperio, Daniela; Talora, Claudio; Bellavia, Diana; Checquolo, Saula; Mori, Mattia; Screpanti, Isabella; Minassi, Alberto; Palermo, Rocco. - In: CANCERS. - ISSN 2072-6694. - 14:23(2022). [10.3390/cancers14235772]
Identification of a novel curcumin derivative influencing notch pathway and DNA damage as a potential therapeutic agent in T-ALL
Zhdanovskaya, NadezdaCo-primo
Writing – Original Draft Preparation
;Lazzari, SaraCo-primo
Investigation
;Firrincieli, MariarosariaInvestigation
;Pace, EleonoraInvestigation
;Imperio, DanielaInvestigation
;Talora, ClaudioWriting – Review & Editing
;Bellavia, DianaWriting – Review & Editing
;Checquolo, SaulaWriting – Review & Editing
;Mori, MattiaWriting – Review & Editing
;Screpanti, IsabellaWriting – Review & Editing
;Palermo, Rocco
Ultimo
Funding Acquisition
2022
Abstract
: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy considered curable by modern clinical management. Nevertheless, the prognosis for T-ALL high-risk cases or patients with relapsed and refractory disease is still dismal. Therefore, there is a keen interest in developing more efficient and less toxic therapeutic approaches. T-ALL pathogenesis is associated with Notch signaling alterations, making this pathway a highly promising target in the fight against T-ALL. Here, by exploring the anti-leukemic capacity of the natural polyphenol curcumin and its derivatives, we found that curcumin exposure impacts T-ALL cell line viability and decreases Notch signaling in a dose- and time-dependent fashion. However, our findings indicated that curcumin-mediated cell outcomes did not depend exclusively on Notch signaling inhibition, but might be mainly related to compound-induced DNA-damage-associated cell death. Furthermore, we identified a novel curcumin-based compound named CD2066, endowed with potentiated anti-proliferative activity in T-ALL compared to the parent molecule curcumin. At nanomolar concentrations, CD2066 antagonized Notch signaling, favored DNA damage, and acted synergistically with the CDK1 inhibitor Ro3306 in T-ALL cells, thus representing a promising novel candidate for developing therapeutic agents against Notch-dependent T-ALL.File | Dimensione | Formato | |
---|---|---|---|
Identification_Identification_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
4.46 MB
Formato
Adobe PDF
|
4.46 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.